Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885462 | 0.82 | KDM4E (0.39) | KDM4EALDH1A1PPARGAGTR1AGTR2 | |
| SCHEMBL3051896 | 0.78 | SMN1; SMN2 (0.40) | KDM4EALDH1A1PPARGLMNAMAPT | |
| SCHEMBL1888097 | 0.78 | PPARG (0.38) | KDM4EALDH1A1PPARGPPARAAGTR1 | |
| SCHEMBL1889761 | 0.75 | KDM4E (0.44) | KDM4EALDH1A1PPARGPPARAAGTR1 | |
| SCHEMBL1885440 | 0.74 | CNR2 (0.40) | KDM4EALDH1A1PPARGAGTR1AGTR2 | |
| SCHEMBL1891790 | 0.74 | PPARG (0.40) | KDM4EALDH1A1PPARGAGTR1AGTR2 | |
| SCHEMBL1883860 | 0.73 | ALDH1A1 (0.35) | KDM4EALDH1A1PPARGLMNA | |
| SCHEMBL3047903 | 0.73 | TRPM8 (0.38) | KDM4EALDH1A1PPARGLMNA | |
| SCHEMBL1885760 | 0.72 | DCTPP1 (0.42) | KDM4EALDH1A1PPARGPPARAAGTR1 | |
| SCHEMBL1883796 | 0.71 | RAB9A (0.38) | KDM4EALDH1A1PPARGAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | KDM4E 4800/4885ALDH1A1 331/4885PPARG 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.